同型半胱氨酸及亚甲基四氢叶酸还原酶基因多态性与缺血性卒中的关系研究

doi:10.3969/j.issn.1673-5765.2017.05.006

摘要/Abstract

摘要：

目的探讨同型半胱氨酸（homocysteine，Hcy）水平及亚甲基四氢叶酸还原酶（methylenetetrahydrofolate reductase，MTHFR）基因多态性与缺血性卒中（ischemic stroke，IS）的关系，并分析Hcy与叶酸、 VitB12之间的相关性。方法运用酶循环法和聚合酶链式反应（polymerase c hain r eaction，PCR）-芯片杂交法分别检测217 例IS患者和223例对照者血浆Hcy与MTHFR C667T基因型，并对照分析两组的基因型频率和等位基因频率分布差异及血浆Hcy水平；运用免疫分析法检测两组中既往未服用过含叶酸和VitB12药物的88例 I S患者和125例对照者血清叶酸、Vi tB12水平，并与Hcy水平进行相关性分析。结果 IS组Hcy浓度高于对照组，差异有显著性（[ 23.95±12.13）μmol/L vs（17.31±7.20）μmol/L， t =29.61，P＜0.001]，IS组与对照组MTHFR 基因型频率CC、CT、TT型分别为14.3％、44.7％、41.0％和 18.4％、48.9％、32.7％，等位基因C与T的频率分别为36.6％、63.4％和42.8％、57.2％，无显著性差异（基因型频率：χ 2=3.59，P =0.166；基因频率：χ 2=3.52，P =0.061）。MTHFR基因TT型（162例）、CT 型（206例）和CC型（72例）的血浆Hcy水平分别为（25.19±12.53）μmol/L、（18.21±8.08）μmol/L和（16.65±6.90）μmol/L，其中TT型显著高于CT型和CC型，CT型显著高于CC型（P 均＜0.001）。I S组和对照组血浆Hcy水平与VitB12呈负相关（I S组和对照组分别为r =-0.431，P＜0.001和r =-0.507，P＜0.001），与叶酸亦呈负相关（IS组和对照组分别为r =-0.489，P＜0.001和r =-0.446，P＜0.001）。结论 IS患者血浆Hcy水平较正常人偏高；MTHFR C667T基因突变、叶酸和VitB12水平降低是血浆Hcy 水平升高的影响因素；MTHFR C667T基因突变可能与缺血性卒中无关。

文章导读： 本研究证实了缺血性卒中患者血浆Hcy水平偏高，MTHFR C667T 基因突变、叶酸和VitB12水平降低是血浆Hcy水平升高的影响因素，而MTHFR C667T基因突变与缺血性卒中无关。

关键词: 缺血性卒中; 同型半胱氨酸; 亚甲基四氢叶酸还原酶; 叶酸; 维生素B12

Abstract:

Objective To investigate the relationship of the plasma homocysteine (Hcy) level and the polymorphism of methylenetetrahydrofolate reductase C667T (MTHFR C667T ) gene with ischemic stroke (IS) in China, and analyze the correlation between Hcy and folate, VitB12. Methods The levels of plasma Hcy in 217 patients with IS and 223 matched controls were detected by enzymatic recycling method, and the MTHFR C667T genotype of the two groups by the method of polymerase chain reaction (PCR)-gene chip, then the level of plasma Hcy, the genotype frequency and the alleles distribution in two groups were compared. The levels of serum folate and VitB12 were detected by immunoassay method in 88 patients with IS and 125 controls who had not taken drugs containing folic acid or VitB12, and the correlation between folate, VitB12 and Hcy were analyzed. Results The plasma Hcy concentration in the IS group was higher than that in control group

([23.95±12.13] μmol/L vs [17.31±7.20] μmol/L, t =29.61, P <0.001); however, the frequency of homozygous and heterozygous MTHFR mutation between the two groups had no significant difference (χ 2=3.59, P =0.166), the frequency of allele C and T in the IS group were 36.6% and 63.4%, respectively, 42.8% and 57.2% in control group, there was also no significant difference in the two groups (χ 2=3.52, P =0.061). There was a significant difference in the corresponding plasma Hcy level of CC, CT, TT genotype, the plasma Hcy level of TT genotype ([25.19±12.53]μmol/L, n =162) was significantly higher than that of CT ([18.21±8.08] μmol/L, n =206) and CC ([16.65±6.90] μmol/L, n =72) genotype, and that of CT genotype was significantly higher than CC genotype (all P <0.001). The Hcy level was negatively correlated with VitB12 in the two groups (the IS: r =-0.431, the control: r =-0.507, both P <0.001) and also negatively correlated with folate(the IS: r = -0.489, the control: r =-0.446, both P <0.001). Conclusion The plasma homocysteine level of IS patients was higher than that of healthy people. The mutation of MTHFR C677T and the declined level of folic acid and VitB12 may contribute to the elevation of homocysteine level. The MTHFR gene mutation may be irrelevant to ischemic stroke.

Key words: Ischemic stroke; Homocysteine; Methylenetetrahydrofolate reductase; Folate; VitB12

张露，崔晓燕，张博爱. 同型半胱氨酸及亚甲基四氢叶酸还原酶基因多态性与缺血性卒中的关系研究[J]. 中国卒中杂志, 2017, 12(05): 404-409.

ZHANG Lu, CUI Xiao-Yan, ZHANG Bo-Ai. Analysis of Relationship of Plasma Homocysteine Level and Polymorphism of Methylenetetrahydrofolate Reductase with Ischemic Stroke[J]. Chinese Journal of Stroke, 2017, 12(05): 404-409.

参考文献

1 Zhang LF，Yang J，Hong Z，et al. Proportion of

different subtypes of stroke in China[J]. Stroke，2003，

34：2091-2096.

2 叶辉，邵娇梅，蒋键刚，等. 血同型半胱氨酸与心脑血

管疾病关系随访研究[J]. 心脏杂志，2006：60-61.

3 Saw SM，Yuan JM，Ong CN，et al. Genetic，

dietary，and other lifestyle determinants of plasma

homocysteine concentrations in middle-aged and

older Chinese men and women in Singapore[J]. Am J

Clin Nutr，2001，73：232-239.

4 Ulvik A，Ueland PM，Fredriksen A，et al. Functional

inference of the methylenetetrahydrofolate reductase

677C>T and 1298A>C polymorphisms from a largescale

epidemiological study[J]. Hum Genet，2007，121：

57-64.

5 朴桂花，金玉，徐英玉. 脑梗死与几种不良生活习惯关

系的统计分析[J]. 中国实用医药，2012，7：249-250.

6 McCully KS. Vascular pathology of homocysteinemia：

implications for the pathogenesis of arteriosclerosis[J].

Am J Pathol，1969，56：111-128.

7 Ashjazadeh N，Fathi M，Shariat A. Evaluation of

Homocysteine Level as a Risk Factor among Patients

with Ischemic Stroke and Its Subtypes[J]. Iran J Med

Sci，2013，38：233-239.

8 Eberhardt RT，Forgione MA，Cap A，et al.

Endothelial dysfunction in a murine model of mild

hyperhomocyst(e)inemia[J]. J Clin Invest，2000，106：

483-491.

9 Hofmann MA，Lalla E，Lu Y，et al.

Hyperhomocysteinemia enhances vascular

inflammation and accelerates atherosclerosis in a

murine model[J]. J Clin Invest，2001，107：675-683.

10 程丝，冯娟，王宪. 高同型半胱氨酸血症治疗研究进

展[J]. 生理科学进展，2011，42：329-334.

11 Cotlarciuc I，Andrew T，Dew T，et al. The basis of

differential responses to folic acid supplementation[J].

J Nutrigenet Nutrigenomics，2011，4：99-109.

12 Zeng R，Xu CH，Xu YN，et al. The effect of folate

fortification on folic acid-based homocysteinelowering

intervention and stroke risk：a metaanalysis[

J]. Public Health Nutr，2015，18：1514-1521.

13 Husemoen LL，Thomsen TF，Fenger

M，et al. Contribution of thermolabile

methylenetetrahydrofolate reductase variant to total

plasma homocysteine levels in healthy men and

women. Inter 99 (2)[J]. Genet Epidemiol，2003，24：

322-330.

14 Goyette P，Frosst P，Rosenblatt DS，et al. Seven novel

mutations in the methylenetetrahydrofolate reductase

gene and genotype/phenotype correlations in severe

methylenetetrahydrofolate reductase deficiency[J].

Am J Hum Genet，1995，56：1052-1059.

15 Lyden PD. In anticipation of International Stroke

Trial-3 (IST-3)[J]. Stroke，2012，43：1691-1694.

16 Konrad C，Muller GA，Langer C，et al. Plasma

homocysteine，MTHFR C677T，CBS 844ins68bp，and MTHFD1 G1958A polymorphisms in spontaneous

cervical artery dissections[J]. J Neurol，2004，251：

1242-1248.

17 马涛. 脑梗死与亚甲基四氢叶酸还原酶基因多态性的

关系[J]. 临床医学，2007，27：82-83.

18 Harbuzova V，Polonikov OV，Stroi DO，et

al. [Analysis of the effect of N5，N10-

methylenetetrahydrofolate reductase gene C(677)-->T

polymorphism on the ischemic stroke development in

persons with various risk factors][J]. Fiziol Zh，2014，

60：18-24.

19 Li Z，Sun L，Zhang H，et al. Elevated plasma

homocysteine was associated with hemorrhagic

and ischemic stroke，but methylenetetrahydrofolate

reductase gene C677T polymorphism was a risk factor

for thrombotic stroke：a Multicenter Case-Control

Study in China[J]. Stroke，2003，34：2085-2090.

20 Tasdemir S，Erdem HB，Sahin I，et al. Correlation

with Platelet Parameters and Genetic Markers of

Thrombophilia Panel (Factor II g. 20210G>A，Factor

V Leiden，MTHFR (C677T，A1298C)，PAI-1，beta-

Fibrinogen，Factor XIIIA (V34L)，Glycoprotein IIIa

(L33P)) in Ischemic Strokes[J]. Neuromolecular Med，

2016，18：170-176.

21 Cardon LR，Bell JI. Association study designs for

complex diseases[J]. Nat Rev Genet，2001，2：91-99.

[1]	吴娱倩, 张玉梅, 范小伟, 王安心, 逄文斌. 运动想象-动觉治疗对缺血性卒中患者手功能康复效果的研究[J]. 中国卒中杂志, 2022, 17(12): 1366-1371.
[2]	伊珞, 周宏宇, 仇鑫, 李子孝, 王拥军. 动脉粥样硬化性疾病的DNA甲基化改变[J]. 中国卒中杂志, 2022, 17(11): 1163-1170.
[3]	王誉博, 李子孝, 王拥军. 表观遗传学与缺血性卒中后氧化应激的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1171-1177.
[4]	崔凌云, 仇鑫, 周宏宇, 李子孝, 王拥军. DNA甲基化与2型糖尿病的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1183-1188.
[5]	刘光亮, 韩凯月, 苏文龙, 张皓. 不同强度有氧踏车训练对不同病程缺血性卒中患者运动和心肺适能的影响 [J]. 中国卒中杂志, 2022, 17(11): 1203-1208.
[6]	徐莹鑫, 张爽, 周晓梅, 袁景林, 赵留庄, 杨海华. 非狭窄性颈动脉斑块与前循环不明原因栓塞性卒中的相关性研究 [J]. 中国卒中杂志, 2022, 17(11): 1233-1237.
[7]	程实, 李静, 郭军平, 胡爱香, 于鑫玮, 韩玮, 梁瑛, 张越巍, 冀瑞俊. 急性卒中患者住院期间感染的临床特征及危险因素分析[J]. 中国卒中杂志, 2022, 17(10): 1065-1070.
[8]	向薇, 徐璐瑶, 张曼曼, 魏红春, 梁志刚. 缺血性卒中急性期磁敏感加权成像不对称突出静脉征的发生率及影响因素分析[J]. 中国卒中杂志, 2022, 17(10): 1097-1102.
[9]	赵永瑞, 刘展会. 弥散张量成像在缺血性卒中患者运动功能预后评估中的研究进展[J]. 中国卒中杂志, 2022, 17(10): 1114-1119.
[10]	张伯煜, 郭玉成, 崔玉霞, 李英丽, 吕雨梅. 急性缺血性卒中患者就医行为决策现状及影响因素研究进展[J]. 中国卒中杂志, 2022, 17(10): 1127-1132.
[11]	吴亭亭, 刘亚飞, 闫世曦, 武一平, 张忠波, 张邯菲, 房娉平. “互联网+”在急性缺血性卒中救治中的应用进展[J]. 中国卒中杂志, 2022, 17(10): 1133-1138.
[12]	徐蔚海, 李顺, 程安琪. 青年卒中的诊治：勿过激[J]. 中国卒中杂志, 2022, 17(09): 915-918.
[13]	张一歌, 张婉, 张璐阳, 王鑫, 丁澜, 王玉莹, 裴璐璐, 方慧, 许予明, 宋波. 责任动脉闭塞与夹层相关缺血性卒中复发的相关性分析[J]. 中国卒中杂志, 2022, 17(09): 932-936.
[14]	吕微, 王安心, 田雪, 张晓丽, 许玉园, 孟霞. 心血宁胶囊对伴高同型半胱氨酸水平缺血性卒中患者短期功能预后的影响[J]. 中国卒中杂志, 2022, 17(09): 972-976.
[15]	张心邈, 潘岳松, 向祥龙, 王拥军, 孟霞. 早期临床路径干预改善卒中医疗服务质量关键绩效指标研究[J]. 中国卒中杂志, 2022, 17(09): 977-984.